Building a New Pancreas Cell Compositions From Reprogrammed Stem Cells Offer Hope for Diabetes Treatment

A pioneering US regenerative medicine company has filed a patent for cell culture compositions derived from dedifferentiated reprogrammed pluripotent stem cells – specifically induced pluripotent stem (iPS) cells that have been converted into pancreatic cell populations. The invention represents a significant step toward a cell therapy approach to diabetes treatment that uses a patient’s own reprogrammed cells to generate the insulin-producing tissue their body lacks.

The Problem

Type 1 diabetes is an autoimmune condition in which the body’s immune system destroys the insulin-producing beta cells of the pancreatic islets. Without these cells, patients cannot produce insulin and must manage their blood glucose through lifelong insulin therapy – an effective but burdensome treatment that still carries risks of hypoglycaemia, hyperglycaemia and long-term complications including cardiovascular disease, kidney failure, blindness and nerve damage.

The ideal treatment for Type 1 diabetes would replace the destroyed beta cells with functional insulin-producing cells – restoring the body’s ability to sense blood glucose and respond automatically with insulin secretion. Islet transplantation from donor pancreases has demonstrated that beta cell replacement can reverse diabetes in some patients, but donor availability is severely limited, the procedure requires lifelong immunosuppression and the transplanted cells are gradually rejected over time.

A cell therapy approach using a patient’s own induced pluripotent stem cells – reprogrammed from ordinary adult cells like skin or blood – could overcome both the donor shortage and the immune rejection problem. The challenge is directing iPS cells reliably through the complex developmental pathway that produces functional pancreatic cells, particularly beta cells capable of glucose-responsive insulin secretion.

What This Invention Does

ViaCyte’s invention describes cell culture compositions – specific populations and mixtures of cells – derived from dedifferentiated reprogrammed pluripotent stem cells such as iPS cells. These cells have been guided through a directed differentiation process to generate pancreatic cell types, creating populations that correspond to developmental stages of pancreatic tissue formation.

The compositions described in the patent represent cell populations at specific stages of the differentiation pathway – from early pancreatic progenitor cells through to more mature pancreatic cell types. By characterising and protecting these intermediate and mature cell populations derived from reprogrammed cells, the invention provides a foundation for developing transplantable pancreatic cell products that could be manufactured from a patient’s own reprogrammed cells.

The use of iPS cells – which can be derived from any patient without requiring embryonic tissue – addresses the ethical and supply constraints that have limited stem cell-based therapies derived from other sources.

Key Features

Induced pluripotent stem cell origin. The cell compositions are derived from iPS cells – reprogrammed from adult somatic cells – enabling the potential for patient-specific cell therapies that avoid immune rejection without requiring immunosuppression.

Pancreatic cell differentiation. The iPS cells are directed to differentiate into pancreatic cell lineages, generating the specific cell types needed for potential insulin-producing cell replacement therapy.

Dedifferentiation and redifferentiation pathway. The process involves first dedifferentiating cells back to a pluripotent state and then redifferentiating them toward pancreatic fates, exploiting the full developmental plasticity of reprogrammed cells.

Defined cell culture compositions. Specific cell compositions – characterised populations at defined stages of differentiation – are described and protected, providing reproducible starting materials for further development into clinical products.

Broad pluripotent cell type coverage. The IPC classifications covering pluripotent cell cultures (C12N 5/00) and differentiated mammalian cell cultures (C12N 5/071) reflect the breadth of cell types and differentiation stages covered by the patent.

Who Is Behind It?

ViaCyte, Inc. was a San Diego-based regenerative medicine company focused on developing stem cell-derived pancreatic cell therapies for diabetes. ViaCyte was known for its encapsulated islet cell transplant programmes and for pioneering the clinical development of stem cell-derived beta cell therapies. The inventors are Alan D. Agulnick, Olivia Kelly, Thomas Schulz, Allan J. Robins and Yuki Ohi. This application is a divisional of AU 2023202507, tracing its origins to US applications filed as early as April 2010. The application is managed by RnB IP Pty Ltd in Canberra.

Why It Matters

Cell replacement therapy for diabetes has long been one of the most compelling goals in regenerative medicine. The ability to generate functional pancreatic cells from a patient’s own reprogrammed stem cells – in unlimited quantities, without immune rejection and without embryonic tissue – would transform the treatment of Type 1 diabetes and potentially certain forms of Type 2 diabetes as well.

ViaCyte was a pioneer in demonstrating that stem cell-derived pancreatic cells could survive and function in human patients, laying the groundwork for the field of stem cell-derived beta cell therapy that is now being actively pursued by multiple companies. The cell compositions described in this patent represent the foundational scientific knowledge underlying this field – knowledge that traces its origins back to discoveries made over a decade ago that are now approaching clinical realisation. With IPC classifications covering differentiated mammalian cell cultures (C12N 5/071) and undifferentiated cell cultures (C12N 5/00), the patent covers the core cell biology of this transformative therapeutic approach.

---

AU 2026201562 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.